CTI 036
Alternative Names: CTI-036Latest Information Update: 29 Sep 2020
At a glance
- Originator Cellics Therapeutics
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 09 Sep 2020 Early research in Methicillin-resistant Staphylococcus aureus infections (Prevention) in USA (Parenteral) before September 2020 (Cellics Therapeutics pipeline, September 2020).